These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9248811)

  • 1. Benign prostatic hyperplasia: natural evolution versus medical treatment.
    Da Silva FC
    Eur Urol; 1997; 32 Suppl 2():34-7. PubMed ID: 9248811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
    Kaplan SA; Olsson CA; Te AE
    J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of benign prostatic hyperplasia: what have we learned in the last decade?
    Kirby RS
    Urology; 2000 Nov; 56(5 Suppl 1):3-6. PubMed ID: 11074195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of different therapies on symptoms of benign prostatic hyperplasia: a prospective study.
    Kawachi I; Barry MJ; Giovannucci E; Rimm EB; Colditz GA; Stampfer MJ; Willett WC
    Clin Ther; 1996; 18(6):1118-27. PubMed ID: 9001828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Watchful waiting in benign prostatic hyperplasia.
    Wiygul J; Babayan RK
    Curr Opin Urol; 2009 Jan; 19(1):3-6. PubMed ID: 19057209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign prostatic hyperplasia: a review.
    Ramsey EW
    Can J Urol; 2000 Dec; 7(6):1135-43. PubMed ID: 11151094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign prostatic hyperplasia in older men.
    Gerber GS
    Clin Geriatr Med; 1998 May; 14(2):317-31. PubMed ID: 9536108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservative Treatment for Benign Prostatic Hyperplasia in Patients With Bladder Stones.
    Yoshida T; Kinoshita H; Nakamoto T; Yanishi M; Sugi M; Murota T; Matsuda T
    Urology; 2015 Sep; 86(3):450-3. PubMed ID: 26235850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benign Prostatic Hyperplasia.
    Langan RC
    Prim Care; 2019 Jun; 46(2):223-232. PubMed ID: 31030823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What's best for your patient with BPH?
    Neal RH; Keister D
    J Fam Pract; 2009 May; 58(5):241-7. PubMed ID: 19442387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Franco JV; Garegnani L; Escobar Liquitay CM; Borofsky M; Dahm P
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD004135. PubMed ID: 34180047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
    Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
    Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.